EE200100219A - Esters of (+) - alpha (2,3-dimethoxyphenyl) -1- [2- (4-fluorophenyl) ethyl] -4-piperidinemethanol, process for their preparation, use and pharmaceutical composition - Google Patents
Esters of (+) - alpha (2,3-dimethoxyphenyl) -1- [2- (4-fluorophenyl) ethyl] -4-piperidinemethanol, process for their preparation, use and pharmaceutical compositionInfo
- Publication number
- EE200100219A EE200100219A EEP200100219A EEP200100219A EE200100219A EE 200100219 A EE200100219 A EE 200100219A EE P200100219 A EEP200100219 A EE P200100219A EE P200100219 A EEP200100219 A EE P200100219A EE 200100219 A EE200100219 A EE 200100219A
- Authority
- EE
- Estonia
- Prior art keywords
- piperidinemethanol
- dimethoxyphenyl
- fluorophenyl
- alpha
- esters
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1998/021608 WO2000021930A1 (en) | 1998-10-14 | 1998-10-14 | Esters of (+)-alpha-( 2,3- dimethoxyphenyl) -1-[2-(4- fluorophenyl) ethyl]-4- piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE200100219A true EE200100219A (en) | 2002-08-15 |
Family
ID=22268079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200100219A EE200100219A (en) | 1998-10-14 | 1998-10-14 | Esters of (+) - alpha (2,3-dimethoxyphenyl) -1- [2- (4-fluorophenyl) ethyl] -4-piperidinemethanol, process for their preparation, use and pharmaceutical composition |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1121345A1 (en) |
| JP (1) | JP2002527422A (en) |
| KR (1) | KR100515429B1 (en) |
| CN (1) | CN1160333C (en) |
| AU (1) | AU1083099A (en) |
| BR (1) | BR9816049A (en) |
| CA (1) | CA2347469C (en) |
| CZ (1) | CZ20011331A3 (en) |
| EA (1) | EA003667B1 (en) |
| EE (1) | EE200100219A (en) |
| HK (1) | HK1039332A1 (en) |
| HR (1) | HRP20010278A2 (en) |
| HU (1) | HUP0200517A3 (en) |
| IL (2) | IL142479A0 (en) |
| NO (1) | NO320417B1 (en) |
| NZ (1) | NZ510631A (en) |
| PL (1) | PL193306B1 (en) |
| SK (1) | SK5082001A3 (en) |
| TR (1) | TR200101047T2 (en) |
| UA (1) | UA57859C2 (en) |
| WO (1) | WO2000021930A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020099076A1 (en) * | 2000-05-25 | 2002-07-25 | Richard Scheyer D. | Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis |
| CN102241667B (en) * | 2010-05-14 | 2013-10-23 | 中国人民解放军军事医学科学院毒物药物研究所 | 1-[(4-hydroxypiperidine-4-yl) methyl] pyridine-2(1H)-one derivatives, preparation method and use thereof |
| CN106892897A (en) * | 2015-12-21 | 2017-06-27 | 上海科胜药物研发有限公司 | A kind of hydroxyl piperazine pyrrone free alkali novel crystal forms and preparation method thereof |
| CN106928187A (en) * | 2015-12-31 | 2017-07-07 | 上海奥博生物医药技术有限公司 | A kind of hydrochloric acid hydroxyl piperazine pyrrone novel crystal forms and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69105501T2 (en) * | 1990-06-01 | 1995-04-13 | Merrell Dow Pharma | (+) - ALPHA- (2,3 DIMETHOXYPHENYL) -1- [2- (FLUOROPHENYL) ETHYL] -4-PIPERIDINE METHANOL. |
-
1998
- 1998-10-14 KR KR10-2001-7004703A patent/KR100515429B1/en not_active IP Right Cessation
- 1998-10-14 EE EEP200100219A patent/EE200100219A/en unknown
- 1998-10-14 EA EA200100361A patent/EA003667B1/en not_active IP Right Cessation
- 1998-10-14 CZ CZ20011331A patent/CZ20011331A3/en unknown
- 1998-10-14 EP EP98953458A patent/EP1121345A1/en not_active Withdrawn
- 1998-10-14 BR BR9816049-4A patent/BR9816049A/en not_active Application Discontinuation
- 1998-10-14 TR TR2001/01047T patent/TR200101047T2/en unknown
- 1998-10-14 IL IL14247998A patent/IL142479A0/en active IP Right Grant
- 1998-10-14 WO PCT/US1998/021608 patent/WO2000021930A1/en active IP Right Grant
- 1998-10-14 CN CNB988142740A patent/CN1160333C/en not_active Expired - Fee Related
- 1998-10-14 PL PL347318A patent/PL193306B1/en not_active IP Right Cessation
- 1998-10-14 AU AU10830/99A patent/AU1083099A/en not_active Abandoned
- 1998-10-14 JP JP2000575839A patent/JP2002527422A/en active Pending
- 1998-10-14 UA UA2001042522A patent/UA57859C2/en unknown
- 1998-10-14 SK SK508-2001A patent/SK5082001A3/en not_active Application Discontinuation
- 1998-10-14 NZ NZ510631A patent/NZ510631A/en active IP Right Revival
- 1998-10-14 HU HU0200517A patent/HUP0200517A3/en unknown
- 1998-10-14 CA CA002347469A patent/CA2347469C/en not_active Expired - Fee Related
-
2001
- 2001-04-05 IL IL142479A patent/IL142479A/en not_active IP Right Cessation
- 2001-04-09 NO NO20011805A patent/NO320417B1/en not_active IP Right Cessation
- 2001-04-12 HR HR20010278A patent/HRP20010278A2/en not_active Application Discontinuation
-
2002
- 2002-02-05 HK HK02100869A patent/HK1039332A1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU1083099A (en) | 2000-05-01 |
| TR200101047T2 (en) | 2001-08-21 |
| PL347318A1 (en) | 2002-03-25 |
| EA200100361A1 (en) | 2001-10-22 |
| SK5082001A3 (en) | 2001-11-06 |
| EA003667B1 (en) | 2003-08-28 |
| HUP0200517A2 (en) | 2002-06-29 |
| PL193306B1 (en) | 2007-01-31 |
| WO2000021930A1 (en) | 2000-04-20 |
| HUP0200517A3 (en) | 2002-12-28 |
| JP2002527422A (en) | 2002-08-27 |
| IL142479A0 (en) | 2002-03-10 |
| BR9816049A (en) | 2001-07-03 |
| NZ510631A (en) | 2003-07-25 |
| CZ20011331A3 (en) | 2001-08-15 |
| NO320417B1 (en) | 2005-12-05 |
| HRP20010278A2 (en) | 2002-06-30 |
| KR20010106517A (en) | 2001-11-29 |
| NO20011805L (en) | 2001-06-08 |
| IL142479A (en) | 2006-06-11 |
| EP1121345A1 (en) | 2001-08-08 |
| UA57859C2 (en) | 2003-07-15 |
| CA2347469C (en) | 2006-02-28 |
| HK1039332A1 (en) | 2002-04-19 |
| CN1314887A (en) | 2001-09-26 |
| KR100515429B1 (en) | 2005-09-20 |
| CA2347469A1 (en) | 2000-04-20 |
| CN1160333C (en) | 2004-08-04 |
| NO20011805D0 (en) | 2001-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69801045D1 (en) | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF AN N-PIPERIDIN-3-PYRAZOLE CARBOXAMIDE DERIVATIVE, ITS SALTS AND THEIR SOLVATES | |
| PT1039909E (en) | METHOD OF PRODUCTION AND COMPOSITION OF AN ORAL PREPARATION OF ITRACONAZOLE | |
| IS5747A (en) | Oxazolidinone derivatives, their method of preparation and pharmaceutical compositions containing them | |
| AU4666996A (en) | Substituted heterocyclic compounds, method of preparing them and pharmaceutical compositions in which they are present | |
| EE9800383A (en) | Method for the Preparation of Biocompatible Biodegradable Microparticles, Microparticles and Materials thereof, Pharmaceutical Composition and Use of Microparticles | |
| EE04990B1 (en) | Pharmaceutical compositions containing an HMG reductase inhibitor, their use and method of preparation | |
| EE04238B1 (en) | Substituted 1,2,3,4-tetrahydronaphthalene derivatives, process for their preparation, pharmaceutical compositions containing said therapeutically active substances and use of said active compounds in therapy | |
| EE9800234A (en) | Method of treatment and pharmaceutical composition | |
| EE9900112A (en) | 2-Cyanoiminoimidazole derivatives, process for their preparation, use and pharmaceutical compositions | |
| EE04717B1 (en) | Indolylpiperidine Compounds, Method of Preparation, Composition and Use thereof | |
| EE200000651A (en) | Azoles, process for their preparation, use and pharmaceutical composition | |
| UA41978C2 (en) | N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidine-1-yl)-ethyl]-2,2-diphenylacetamide hydrochloride, a PROCESS for the preparation thereof and a pharmaceutical composition | |
| EE04812B1 (en) | 2-Phenylpyran-4-one derivatives, process for their preparation and use, use of intermediates and pharmaceutical composition | |
| HUP9902135A3 (en) | Use of (+)-alfa-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)-ethyl]-4-piperidinemethanol for producing pharmaceutical compositions suitable for treatment depressive disorders and bipolar disorders | |
| EE03996B1 (en) | Pharmaceutical compositions, process for their preparation and use | |
| HUP0202988A3 (en) | Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one derivatives and their use as lipase inhibitors, process for their preparation and pharmaceutical compositions containing them | |
| HUP0400889A3 (en) | Processes for the preparation of (r)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and pharmaceutical compositions containing the compound | |
| FI956278A (en) | Substituted 4-phenylthiazole derivatives, process for their preparation and pharmaceutical compositions containing them | |
| EE200100219A (en) | Esters of (+) - alpha (2,3-dimethoxyphenyl) -1- [2- (4-fluorophenyl) ethyl] -4-piperidinemethanol, process for their preparation, use and pharmaceutical composition | |
| PT1017681E (en) | PHARMACEUTICAL AND INTERMEDIATE COMPOUNDS | |
| HUP0103712A3 (en) | Salts of paroxetine, process for their preparation and their pharmaceutical use | |
| EE200100544A (en) | 15-membered 8α-and 9α-lactams, their method of preparation and pharmaceutical composition | |
| EE04095B1 (en) | Use of ketolides and pharmaceutically acceptable salts thereof for the preparation of pharmaceutical compositions | |
| EE200000752A (en) | Alpha-D-xylose compounds, process for their preparation and use, and pharmaceutical composition | |
| FI972129A0 (en) | 6-Methoxy-1H-benzotriazole-5-carboxamide derivatives, process for their preparation and pharmaceutical compositions containing them |